我们的TLR9显效药是基于免疫共刺激序列（ISS）的。ISS是一短DNA序列，它提高免疫系统能力来对抗疾病并控制慢性炎症。
Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
我们的TLR9显效药是基于免疫共刺激序列（ISS）的。ISS是一短DNA序列，它提高免疫系统能力来对抗疾病并控制慢性炎症。
Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
应用推荐